Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.30
    OpenPayerBilling CodesDiseases and Disorders of the Kidney and Urinary TractDRG 658-kidney-and-ureter-procedures-for-neoplasm-without-cc-mcc
    Ask Trek AI about this page

    Kidney and Ureter Procedures for Neoplasm without CC/MCC: Inpatient Reimbursement Overview

    DRG 658 encompasses kidney and ureter procedures performed for neoplasm without Complication or Comorbidity or Major Complication or Comorbidity, defining a lower-complexity surgical admission. It matters for inpatient reimbursement because Diagnosis-Related Group assignment determines standardized Medicare payment based on clinical case mix and documented resource intensity.

    Customize your policy alerts

    Sign up for drg 658 policy alerts

    Get alerted when payer policies referencing 658 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    DRG 658 Overview

    DRG 658 covers inpatient admissions for kidney and ureter surgical procedures performed for neoplasm when no Complication or Comorbidity and no Major Complication or Comorbidity are present. This Diagnosis-Related Group groups cases by clinical complexity and resource use to determine standardized Medicare payment for the hospitalization. It is important for hospitals because the classification affects base payment and impacts coding, billing, and expected reimbursement for urologic oncology surgeries. Accurate principal diagnosis and procedure coding determine assignment to this Diagnosis-Related Group and corresponding payment.

    Table of contents

    Progress1 / 3

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • Facility ComparisonBeds, revenue & payer mix
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical Trials

    • Perioperative randomized trials comparing minimally invasive nephrectomy techniques versus open surgery for localized renal neoplasm: These studies evaluate surgical approach (laparoscopic/robotic partial or radical nephrectomy versus open procedures) in adults with localized kidney tumors without significant comorbid complications, measuring intraoperative metrics, hospital length of stay, perioperative complications, and short-term oncologic outcomes. This research is relevant because surgical approach directly affects inpatient resource use, complication rates that drive CC/MCC classification, and reimbursement implications for DRG 658.
    • Comparative effectiveness studies of renal-sparing surgery versus radical nephrectomy in small renal masses focusing on functional and economic outcomes: Observational cohorts or pragmatic trials enrol patients with T1 renal neoplasms eligible for either partial nephrectomy or radical nephrectomy to compare postoperative renal function preservation, readmission rates, downstream dialysis risk, and total episode-of-care costs. Payers and providers need this evidence to balance immediate inpatient costs and longer-term morbidity that influence post-acute utilization and overall value of care under this DRG.
    • Post-discharge outcomes and survivorship studies assessing readmissions, complications, and health-related quality of life after kidney/ureter cancer surgery: Prospective registry-based or longitudinal cohort studies follow patients discharged after nephrectomy or ureteral tumor surgery to identify predictors of 30- and 90-day readmission, late surgical complications, surveillance adherence, and survivorship needs. These studies inform care pathways, discharge planning, and resource allocation because readmissions and complications alter inpatient case-mix, affect reimbursement patterns, and are key targets for cost and quality improvement for DRG 658.

    Related Codes

    650-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITH-MCC

    Kidney Transplant with Hemodialysis with Major Complication or Comorbidity: Inpatient Reimbursement Overview

    651-KIDNEY-TRANSPLANT-WITH-HEMODIALYSIS-WITHOUT-MCC

    Kidney Transplant with Hemodialysis without MCC: Inpatient Reimbursement Overview

    652-KIDNEY-TRANSPLANT

    Kidney Transplant: Inpatient Reimbursement Overview

    653-MAJOR-BLADDER-PROCEDURES-WITH-MCC

    Major Bladder Procedures with MCC: Inpatient Reimbursement Overview

    654-MAJOR-BLADDER-PROCEDURES-WITH-CC

    Major Bladder Procedures with CC: Inpatient Reimbursement Overview

    655-MAJOR-BLADDER-PROCEDURES-WITHOUT-CC-MCC

    Major Bladder Procedures without CC/MCC: Inpatient Reimbursement Overview

    656-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Neoplasm with MCC: Inpatient Reimbursement Overview

    657-KIDNEY-AND-URETER-PROCEDURES-FOR-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Neoplasm with CC: Inpatient Reimbursement Overview

    659-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-MCC

    Kidney and Ureter Procedures for Non-Neoplasm with MCC: Inpatient Reimbursement Overview

    660-KIDNEY-AND-URETER-PROCEDURES-FOR-NON-NEOPLASM-WITH-CC

    Kidney and Ureter Procedures for Non-Neoplasm with CC: Inpatient Reimbursement Overview

    Showing 1–10 of 41

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.